Germany · Delayed Price · Currency is EUR Spago Nanomedical AB Statistics
Total Valuation
FRA:7UX has a market cap or net worth of EUR 3.52 million. The enterprise value is 2.50 million.
| Market Cap | 3.52M |
| Enterprise Value | 2.50M |
Important Dates
The next estimated earnings date is Monday, February 2, 2026.
| Earnings Date | Feb 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 348.20M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +46.37% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 68.15% |
| Owned by Institutions (%) | 9.02% |
| Float | 110.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.66 |
| PB Ratio | 3.15 |
| P/TBV Ratio | 3.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.97 |
| EV / Sales | 4.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.93 |
Financial Position
The company has a current ratio of 3.95
| Current Ratio | 3.95 |
| Quick Ratio | 2.69 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -242.48 |
Financial Efficiency
Return on equity (ROE) is -106.57% and return on invested capital (ROIC) is -66.88%.
| Return on Equity (ROE) | -106.57% |
| Return on Assets (ROA) | -55.58% |
| Return on Invested Capital (ROIC) | -66.88% |
| Return on Capital Employed (ROCE) | -219.22% |
| Revenue Per Employee | 66,052 |
| Profits Per Employee | -322,163 |
| Employee Count | 13 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.65% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -50.65% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 43.24 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:7UX had revenue of EUR 528,414 and -2.58 million in losses. Loss per share was -0.01.
| Revenue | 528,414 |
| Gross Profit | -570,292 |
| Operating Income | -2.59M |
| Pretax Income | -2.58M |
| Net Income | -2.58M |
| EBITDA | -2.57M |
| EBIT | -2.59M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 1.02 million in cash and n/a in debt, giving a net cash position of 1.02 million.
| Cash & Cash Equivalents | 1.02M |
| Total Debt | n/a |
| Net Cash | 1.02M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.12M |
| Book Value Per Share | 0.00 |
| Working Capital | 1.12M |
Cash Flow
In the last 12 months, operating cash flow was -2.67 million and capital expenditures -20,713, giving a free cash flow of -2.69 million.
| Operating Cash Flow | -2.67M |
| Capital Expenditures | -20,713 |
| Free Cash Flow | -2.69M |
| FCF Per Share | n/a |
Margins
| Gross Margin | -107.93% |
| Operating Margin | -489.76% |
| Pretax Margin | -487.74% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:7UX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -46.37% |
| Shareholder Yield | -46.37% |
| Earnings Yield | -73.20% |
| FCF Yield | -76.41% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |